QUANTUM X LABS INC. quarterly report, Q1 FY2018

Business Context and Reporting Period

Company: Virtual Crypto Technologies, Inc. (formerly Emerald Medical Applications Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2018
Business Overview: The Company pivoted from its former medical operations (DermaCompare) to a new focus on cryptocurrency trading technology. In January 2018, it formed a wholly-owned Israeli subsidiary, Virtual Crypto Technologies Ltd., to develop software and hardware for cryptocurrency transactions via ATMs and mobile devices. The Company changed its name and trading symbol (VRCP) in March 2018. The former subsidiary, Emerald Israel, ceased operations and is currently in liquidation.

Key Financial Metrics

Metric Q1 2018 Q1 2017
Revenue $0 $0
Net Loss $(20,802,376) $(557,887)
Operating Expenses $1,428,294 $68,650
Finance Expense (Net) $(19,374,082) $(198,450)
Cash and Cash Equivalents (End of Period) $1,449,795 $585
Total Assets $1,478,498 $29,530
Total Liabilities $921,270 $1,618,106
Working Capital $557,228 $(996,760)

Note: The Net Loss for Q1 2018 is heavily impacted by a non-cash finance expense of approximately $19.4 million related to the modification of convertible notes.

Material Changes vs. Prior Period

  • Revenue Generation: The Company generated no revenue in either period. However, it recorded $50,000 in deferred revenue in Q1 2018 from a distribution agreement with Chiron Refineries Ltd.
  • Expense Surge: Operating expenses increased from $68,650 to $1.43 million, driven by new R&D costs ($54k) and significant non-cash stock-based compensation for consultants ($892k) related to the new business setup.
  • Finance Expense Spike: Finance expenses jumped from $198k to $19.4 million. This was primarily due to the accounting treatment of modifying existing convertible notes (extinguishment of old debt and issuance of new debt), which triggered a $18.4 million charge, and the fair value adjustment of a cancelled derivative liability ($2.2 million).
  • Liquidity Improvement: Cash balances increased from $2,959 at year-end 2017 to $1.45 million at March 31, 2018, following a capital raise of approximately $1.9 million in equity and debt.
  • Discontinued Operations: The Company ceased its former medical operations (Emerald Israel) in January 2018. Assets and liabilities related to this entity are now classified as "held for sale."

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

Management is focused on commercializing the "NetoBit Trader" technology for cryptocurrency transactions. The Company secured a binding term sheet with Chiron Refineries Ltd. for exclusive distribution in Turkey and Northern Cyprus, with an option for Nigeria. The Company expects to finance future operations through equity sales, convertible debt, or strategic alliances.

Risks and Contingencies

  • Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern. Additional funding is required to support commercialization and R&D.
  • Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2018, due to material weaknesses and a lack of resources/personnel.
  • Liquidation Proceedings: The former subsidiary, Emerald Israel, is under a winding-up order by the District Court of Lod. While the Company does not anticipate excess proceeds from the liquidation, it remains a contingency.
  • Legal Proceedings: A former CEO (Lior Wayn) filed a wrongful dismissal lawsuit claiming $100,000 in damages. The Company intends to defend against this claim.

Unusual Items

The massive net loss is non-recurring and non-cash in nature, driven by the restructuring of debt instruments and the cancellation of preferred stock and warrants. The Company raised $1.67 million in cash via a $0.07 per unit offering and issued significant shares for services.

Investor Verification Checklist

  • Capital Adequacy: Verify if the Company has secured the additional funding required to maintain operations beyond the current cash balance of $1.45 million.
  • Debt Restructuring Impact: Confirm the terms of the new convertible notes and the potential for future dilution given the low conversion price ($0.01) and the volume of shares issued.
  • Revenue Realization: Monitor the status of the Chiron Refineries distribution agreement to determine if the $250,000 appointment fee will be fully collected and if product sales will commence.
  • Internal Controls: Assess the timeline and plan for remediation of the ineffective disclosure controls and procedures.
  • Liquidation Outcome: Track the liquidation of Emerald Israel to ensure no unexpected liabilities or claims impact the parent company.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.